GlassScriptPhysician profile
Ramona Arias
NPI 1154392801
$6,756.17
in general payments reported to CMS, 2019-2025
40 companies · $1,330 in 2025
The $1,330 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $428 · 2021: $936 · 2022: $911 · 2023: $1,168 · 2024: $1,876 · 2025: $1,330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,322 · Education: $51.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,322.36 |
| Education | $51.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $907.43 | 2019-2025 | Farxiga, Airsupra, Fasenra |
| Abbvie INC. | $756.72 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Mallinckrodt Hospital Products INC. | $526.87 | 2021-2025 | Acthar |
| Lilly USA, LLC | $429.96 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $304.00 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $296.59 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $267.83 | 2019-2024 | Jynarque, Rexulti |
| Amgen INC. | $242.39 | 2022-2025 | Krystexxa, Tavneos |
| Pfizer INC. | $208.34 | 2019-2025 | |
| Glaxosmithkline, LLC. | $202.18 | 2020-2025 | Trelegy Ellipta |
| Sumitomo Pharma America, INC. | $178.89 | 2024-2025 | Gemtesa |
| Corcept Therapeutics | $164.32 | 2024-2025 | Korlym |
| Horizon Therapeutics Plc | $159.30 | 2020-2023 | Krystexxa |
| Renalytix Ai, INC. | $158.82 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
| Abbott Laboratories | $156.86 | 2022-2024 | Freestyle Libre 2 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramona Arias listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.